Lonza Launches Enhanced DNA-to-IND Programme with GS Ori-Go Vector Technology to Accelerate Biologics Development

Lonza查看公司主页 has announced a significant strengthening of its biologics services with an enhanced preclinical development offering, designed to help customers make more confident early-stage decisions while accelerating timelines and reducing development risk. The enhanced approach combines early, decision-enabling insights with accelerated execution, addressing uncertainty at the point in the development journey where choices have the greatest impact on downstream success.

Raymond Donninger, Senior Director of Commercial Development for Integrated Biologics at Lonza查看公司主页, commented: "We know that the earliest decisions in biologics development are often the hardest and the most critical. With this enhanced DNA-to-IND offering, we're helping our customers make those decisions sooner and with greater clarity, while bringing meaningful innovation to them faster."

Early De-Risking Where Decisions Matter Most

Lonza查看公司主页's new early de-risking package delivers data-driven, integrated insights across development, manufacturing, and regulatory processes to help reduce uncertainty at crucial early-stage decision points. By providing a comprehensive picture of safety, manufacturability, and regulatory readiness early on, the package contributes to providing early-phase companies and their stakeholders with greater confidence that the lead drug candidate they are advancing is both viable and scalable.

This approach enables evidence-based candidate selection and establishes a more predictable path towards first-in-human studies. The importance of such early intervention is underscored by the fact that issues affecting manufacturing feasibility, product stability, immunogenicity, and immunosafety are common pitfalls in biologics development. If addressed late, these can require cell line rework, process redevelopment, or product reformulation, potentially introducing delays, regulatory complications including clinical holds, and lost momentum.

Accelerated DNA-to-IND Timelines Without Compromise

Lonza查看公司主页's enhanced DNA-to-IND offering enables monoclonal antibody programmes to achieve IND readiness in as little as 6 months, with toxicology-grade drug substance available in approximately 2 months. These accelerated timelines are delivered through lean, streamlined process development and proven platform technologies, without compromising product quality or compliance standards.

The offering builds on Lonza查看公司主页's established preclinical development expertise, integrating development, manufacturing, and regulatory insight from the outset to help deliver faster, more predictable progress. Combined with Lonza's end-to-end development and manufacturing expertise, the DNA-to-IND programme enables early-stage pharma and biotech companies to rapidly progress from early discovery to clinical readiness.

GS Ori-Go (搜索)搜索该药品: Evolved Expression Technology

As a cornerstone of the enhanced offering, Lonza查看公司主页 has launched GS Ori-Go (搜索)搜索该药品, a next-generation vector platform for the GS Gene Expression System, which has supported more than 100 commercial products. This evolved technology is designed to further improve efficiency, consistency, and confidence in early-stage biomanufacturing compared to the current GS expression system.

The new vector technology supports lead-clone titers higher than 11 g/L and allows direct progression from bulk pools to clonal cell lines, removing the need for enriched pools and methionine sulfoximine查看药品详情 (MSX) selection. The platform demonstrates strong bulk pool stability and more than a 30% increase in titers across multiple modalities, including monoclonal antibodies, bispecifics, and fusion proteins.

GS Ori-Go (搜索)搜索该药品 enables faster development of high-quality cell lines with fewer steps, helping customers streamline workflows while maintaining strong performance and reliability. By strengthening productivity and predictability early in development, the new GS Ori-Go vectors reinforce Lonza查看公司主页's integrated approach to accelerating DNA-to-IND timelines while reducing downstream risk.

Strategic Imperative for Complex Biologics

The launch comes at a time when biotherapeutic drug development is becoming increasingly complex, with advanced formats such as bispecifics, antibody-drug conjugates, and fusion proteins introducing additional layers of developability and manufacturing risk. The pressures are particularly acute during early development when timelines are tightly coupled to funding milestones, partnerships, and valuation.

Investor confidence is critical at this stage, and programmes that demonstrate a clear path to IND submission stand out. Early derisking has become a strategic imperative, driving a shift towards proactive risk mitigation, particularly among biotechs partnering with CDMOs. These collaborations increasingly rely on integrated approaches that bring together developability assessment, optimisation, and manufacturing expertise within a single strategy.

Donninger added: "By combining early de-risking, accelerated execution, and technologies like our new GS Ori-Go (搜索)搜索该药品 vectors, we're enabling teams to progress high-quality biologics programmes to the clinic with greater speed, confidence, and control."